Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-01-27
1996-02-13
Prescott, Arthur C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514563, A61K 3702, A61K 31195, A61K 3122
Patent
active
054911508
ABSTRACT:
A supplementary therapeutic agent for the treatment of immunodeficiency syndrome with reduced NK (natural killer) activity and an immunopotentiator preparation containing it are provided.
A supplementary therapeutic agent for immunopotentiation which comprises L-cysteine, L-cystine, or L-glutamine, or salts thereof and is used in combination with an immunopotentiator such as lentinan, OK-432, sizofiran or the like, and an immunopotentiator preparation containing the agent. This combination of agents is useful as a supplementary therapeutic agent for the treatment of an immunodeficiency, such as low NK activity syndrome, chronic fatigue syndrome, acquired immunodeficiency syndrome, or congenital immunodeficiency syndromes.
REFERENCES:
patent: 3952115 (1976-04-01), Damico et al.
patent: 4724239 (1988-02-01), Morgan
patent: 4827016 (1989-05-01), Morgan
Biol. Chem. Hoppe-Seyler, vol. 370, No. 2, Feb. 1989, pp. 101-108, H.-P. ECk, et al., "Low Concentrations of Acid-Soluble Thiol (Cysteine) in the Blood Plasma of HIV-1 Infected Patients".
Database WPI, Derwent Publications, AN 84-173727 & JP-A-59-95220, Jun. 1, 1984.
Database WPI, Derwent Publications, AN 88-025682 & JP-A-62 286923, Dec. 12, 1987.
Proceedings of the Seventh Symposium on Host Defense Mechanisms Against Cancer, Nakone, Nov. 8-10, 1985, pp. 221-229, Tetsuo Taguchi, et al., "Lentinan: An Overview of Experimental and Clinical Studies of its Action Against Cancer".
Clinical Research, vol. 40, No. 2, 1992, p. 246A, J. G. Thoene, "In Vitro Effectiveness of Aminothiols and Disulfides Against HIV-1".
VII International Conference on AIDS, Florence, Italy, Jun. 16-21, 1991, Abstract No. W.A. 1050, La Colla Paola, et al., "In Vitro Effects of N-Acetyl Cysteine (NAC), Alone or in Combination with AZT, on Cell Growth and HIV-1 Multiplication".
International Immunology, vol. 4, No. 1, 1992, pp. 7-13, H.-P. Eck, et al., "T4+ Cell Numbers are Correlated with Plasma Glutamate and Cystine Levels: Association of Hyperglutamataenia with Immunodeficiency in Diseases with Different Aetiologies".
Aoki Tadao
Miyakoshi Hideo
Ajinomoto Co. Inc.
Prescott Arthur C.
LandOfFree
Supplementary therpeutic agents for the treatment of immunodefic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Supplementary therpeutic agents for the treatment of immunodefic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Supplementary therpeutic agents for the treatment of immunodefic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-240784